Carlton L. Schwab

发表

SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression

E. Ratner, Serena Wong, D. Silasi, 2016, Molecular Cancer Therapeutics.

Acute exposure to ethanol affects Toll-like receptor signaling and subsequent responses: an overview of recent studies.

Q. Zheng, Carlton L. Schwab, S. Pruett, 2004, Alcohol.

T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2

S. Canevari, P. Schwartz, T. Rutherford, 2014, Clinical & Experimental Metastasis.

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas

E. Ratner, D. Silasi, P. Schwartz, 2015, British Journal of Cancer.

T-DM1, a novel antibody–drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo

E. Ratner, D. Silasi, P. Schwartz, 2014, Cancer medicine.

Patterns of immunotoxicity associated with chronic as compared with acute exposure to chemical or physical stressors and their relevance with regard to the role of stress and with regard to immunotoxicity testing.

Q. Zheng, Carlton L. Schwab, S. Pruett, 2009, Toxicological sciences : an official journal of the Society of Toxicology.

Suppression of Innate Immunity by Acute Ethanol Administration: A Global Perspective and a New Mechanism Beginning with Inhibition of Signaling through TLR31

Q. Zheng, Carlton L. Schwab, S. Pruett, 2004, The Journal of Immunology.

with Inhibition of Signaling through TLR3 Perspective and a New Mechanism Beginning Ethanol Administration: A Global Suppression of Innate Immunity by Acute

Q. Zheng, Carlton L. Schwab, S. Pruett, 2004 .

Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo.

E. Ratner, D. Silasi, P. Schwartz, 2015, Gynecologic oncology.

Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo.

P. Schwartz, T. Rutherford, E. Cocco, 2014, Gynecologic oncology.

Sodium methyldithiocarbamate inhibits MAP kinase activation through toll-like receptor 4, alters cytokine production by mouse peritoneal macrophages, and suppresses innate immunity.

Q. Zheng, Carlton L. Schwab, S. Pruett, 2005, Toxicological sciences : an official journal of the Society of Toxicology.

Ethanol suppresses cytokine responses induced through Toll-like receptors as well as innate resistance to Escherichia coli in a mouse model for binge drinking.

Q. Zheng, Carlton L. Schwab, S. Pruett, 2004, Alcohol.

Differences in IL-10 and IL-12 production patterns and differences in the effects of acute ethanol treatment on macrophages in vivo and in vitro.

Q. Zheng, Carlton L. Schwab, S. Pruett, 2005, Alcohol.

Effects of Slide Storage on Detection of Molecular Markers by IHC and FISH in Endometrial Cancer Tissues From a Clinical Trial: An NRG Oncology/GOG Pilot Study

O. Olopade, A. Montag, M. Birrer, 2021, Applied immunohistochemistry & molecular morphology : AIMM.

Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial–mesenchymal transition

S. Mane, T. Boggon, Kaya Bilgüvar, 2016, Proceedings of the National Academy of Sciences.

Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo

E. Ratner, R. Angioli, D. Silasi, 2015, Molecular Cancer Therapeutics.

Dual HER 2 / PIK 3 CA Targeting Overcomes Single-Agent Acquired Resistance in HER 2-Ampli fi ed Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo

E. Ratner, R. Angioli, D. Silasi, 2015 .

Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo

Pei Hui, Jonathan Black, David L Rimm, 2016, British Journal of Cancer.

The Role of the Immune System in Ovarian Cancer and Implications on Therapy

A. Santin, J. Black, G. Menderes, 2016, Expert review of clinical immunology.

Past, present and future targets for immunotherapy in ovarian cancer.

A. Santin, Carlton L. Schwab, D. Roque, 2014, Immunotherapy.

Polymerase ε (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients.

E. Ratner, D. Silasi, P. Schwartz, 2015, Gynecologic oncology.

Immunotherapy and targeted therapy for cervical cancer: an update

A. Santin, J. Black, G. Menderes, 2016, Expert review of anticancer therapy.

Molecular diagnosis and molecular profiling to detect treatment-resistant ovarian cancer

Jonathan Black, A. Santin, J. Black, 2016, Expert review of molecular diagnostics.

Immune checkpoint inhibitors in gynecologic cancers with lessons learned from non-gynecologic cancers

A. Santin, J. Black, G. Menderes, 2016, Expert opinion on biological therapy.

Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancer

Gloria S. Huang, E. Ratner, D. Silasi, 2018, Journal of Cancer Research and Clinical Oncology.

Overexpression of HE4 (human epididymis protein 4) enhances proliferation, invasion and metastasis of ovarian cancer

Carlton L. Schwab, Huimin Wang, Xiao Li, 2015, Oncotarget.

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas

E. Ratner, D. Silasi, P. Schwartz, 2015, British Journal of Cancer.

Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo.

R. Angioli, P. Schwartz, T. Rutherford, 2014, Gynecologic oncology.

An update on the current pharmacotherapy for endometrial cancer

A. Santin, J. Black, Carlton L. Schwab, 2016, Expert opinion on pharmacotherapy.

Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro

E. Ratner, D. Silasi, P. Schwartz, 2015, Tumor Biology.

Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy‐resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo

E. Ratner, D. Silasi, T. Rutherford, 2015, Cancer.

Modeling and predicting stress-induced immunosuppression in mice using blood parameters.

Q. Zheng, Carlton L. Schwab, S. Pruett, 2004, Toxicological sciences : an official journal of the Society of Toxicology.

Taxanes: their impact on gynecologic malignancy

A. Santin, Carlton L. Schwab, D. Roque, 2014, Anti-cancer drugs.

T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2

S. Canevari, P. Schwartz, T. Rutherford, 2014, Clinical & Experimental Metastasis.

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas

E. Ratner, D. Silasi, P. Schwartz, 2015, British Journal of Cancer.

Benzene exposure and risk of lymphohaematopoietic cancers in 25 000 offshore oil industry workers

N. Rothman, Q. Lan, E. Ratner, 2015, British Journal of Cancer.

Incidental injury and repair of obturator nerve during laparoscopic pelvic lymphadenectomy.

G. Menderes, Carlton L. Schwab, M. Azodi, 2016, Gynecologic Oncology.

Dual-Targeting Nanoparticles for In Vivo Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells

E. Ratner, W. Saltzman, D. Silasi, 2016, Molecular Cancer Therapeutics.

Clostridium Perfringens Enterotoxin (CPE) and CPE-Binding Domain (c-CPE) for the Detection and Treatment of Gynecologic Cancers

E. Cocco, A. Santin, J. Black, 2015, Toxins.

Clostridium perfringens enterotoxin C‐terminal domain labeled to fluorescent dyes for in vivo visualization of micrometastatic chemotherapy‐resistant ovarian cancer

C. Zeiss, E. Ratner, W. Saltzman, 2015, International journal of cancer.

Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.

E. Ratner, D. Silasi, P. Schwartz, 2016, American journal of obstetrics and gynecology.

Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro

E. Ratner, D. Silasi, P. Schwartz, 2015, Journal of experimental & clinical cancer research : CR.

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas

E. Ratner, D. Silasi, M. Azodi, 2015, British Journal of Cancer.

Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo

E. Ratner, D. Silasi, T. Rutherford, 2014, British Journal of Cancer.

Membranous expressions of Lewis y and CAM-DR-related markers are independent factors of chemotherapy resistance and poor prognosis in epithelial ovarian cancer.

Zhen-hua Hu, Carlton L. Schwab, Juan-juan Liu, 2015, American journal of cancer research.

Targeted therapy in the treatment of uterine serous carcinoma.

A. Santin, Carlton L. Schwab, 2015, Pharmacogenomics.

Taxanes: their impact on gynecologic malignancy

A. Santin, Carlton L. Schwab, D. Roque, 2014, Anti-cancer drugs.

Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro

E. Ratner, D. Silasi, P. Schwartz, 2015, Journal of experimental & clinical cancer research : CR.

E. Ratner, D. Silasi, T. Rutherford, 2015, Cancer.